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http:WHAT THIS PAPER ADDS
Durability of endovascular aortic repair (EVAR) is supposed to be device-dependent. However, data on long-term
regression of aneurysmal sac after endovascular repair are lacking. Results of this study suggested relevant
shrinkage (5 mm or more) persisting without aid of additional reinterventions to be assumed in the future as a
valuable indicator of EVAR success, and demonstrated equal efﬁcacy in long-term shrinkage rates among
different models of current generation devices.Background: Regression of the aneurysmal sac after endovascular repair of abdominal aortic aneurysm (AAA) is
an accepted indicator of aneurysm exclusion. This study evaluated the spontaneous decrease in sac diameter
over a 10-year period in patients undergoing endovascular aneurysm repair (EVAR) with different stentgrafts.
Methods: 1,450 patients (mean age 73.1  7.7 years; 1,325 male) undergoing EVAR and with a minimum of 1-
year computed tomography (CT) imaging were included. Different implanted stentgrafts (n ¼ 622 [42.9%] Zenith,
n ¼ 236 [16.3%] AneuRx, n ¼ 179 [12.3%] Talent, n ¼ 83 [5.7%] Endurant, n ¼ 236 [16.3%] Excluder, n ¼ 36
[2.5%] Fortron, 53 [3.7%] Anaconda, n ¼ 5 [0.3%] others) were employed. “Persisting shrinkage” was measured
as 5 mm AAA diameter regression spontaneously persisting or increasing until the end of follow-up without
reintervention. Persisting shrinkage among devices was compared with survival and Cox regression analyses.
Results: During a median follow-up of 45 months (interquartile range, IQR, 21e79) persisting shrinkage was
detected in 768 (53%) aneurysms. KaplaneMeier estimates of persisting shrinkage were 25.8% at 1 year, 63% at 3
years and 72.6% at 10 years. Persisting shrinkage rates were signiﬁcantly higher for Zenith (p < .0001), Endurant
(p ¼ .013) and new generation Excluder (p < .0001) devices. Cox analyses conﬁrmed that persisting shrinkage
rates were independently associated with Zenith (OR 1.33; 95% CI: 1.176e1.514) and Endurant (OR 1.52; 95% CI:
1.108e2.092) stentgrafts and negatively associated with the AneuRx (OR 0.57; 95% CI: 0.477e0.688) device.
Survival rates were higher in the persisting shrinkage group: 84.1% vs. 77.8% at 3 years, and 53% vs. 38.1% at 10
years (p < .0001). Freedom from AAA-related-death rate was 100% at 3 years and 99.7% at 10 years in the
persisting shrinkage group.
Conclusions: Aneurysm diameter shrinkage can be achieved in most current EVARs with persisting effect at 10
years from repair and indicates the beneﬁt and safety of treatment. Last generation devices seem to be
important factors in inducing aneurysm sac shrinkage with similar clinically relevant effects among single models.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2013.05.012Standardized Reporting practices in Vascular Surgery sug-
gests reduction in abdominal aortic aneurysm (AAA) size as
an indicator of the integrity and function of the endovas-
cular graft.1 Regression of the aneurysmal sac around the
stentgraft is presumed to imply exclusion from the blood
circulation and absence of pressurization. Several authors
have documented AAA regression at early follow-up after
EVAR with different stentgraft models.2,3 However, aneu-
rysm regression does not always stably persist after EVAR.
Stabilization or even expansion of aneurysm sac after an
initial phase of signiﬁcant shrinkage as well as a number of
additional aorto-iliac morphological changes (aortic
neck enlargement, shortening, increasing aortic or iliac
E. Cieri et al. 193tortuosity, etc.),1,4,5 challenging the stability of endovascular
repair, are likely to develop over time after initial successful
stentgraft deployment. Thereby, rates of sac shrinkage
detected in the early 2e3 years after repair cannot be
assumed as reliable proof of EVAR efﬁcacy in aneurysm
treatment.
The aim of this study was to analyze the occurrence of
aneurysmal sac shrinkage persisting in the long term after
EVAR and to compare rates obtained with different device
models.
METHODS
Data from consecutive patients undergoing endovascular
repair of infrarenal AAA from 1997 to 2011 at a single
center with at least 1-year of computed tomography (CT)
imaging studies were reviewed. A total of 1,609 EVARs were
performed during the study period. Patients treated with
fenestrated stentgraft or who did not reach 1-year follow-
up imaging were excluded, leaving a total of 1,450 pa-
tients for the present study.
All patients had a preoperative evaluation with CT angi-
ography within 1 month before treatment to assess EVAR
feasibility. EVAR was applied with different device models,
the choice of each depending on the aorto-iliac
morphology, stentgraft availability and operator prefer-
ences: n ¼ 622 (42.9%) Zenith (Cook Inc, Bloomington, IN);
n ¼ 236 (16.3%) AneuRx (Medtronic Vascular, Santa Rosa,
CA); n ¼ 179 (12.3%) Talent (Medtronic Vascular, Santa
Rosa, CA); n ¼ 83 (5.7%) Endurant (Medtronic Vascular,
Santa Rosa, CA); n ¼ 236 (16.3%) Excluder (Gore & Asso-
ciates, Inc, Flagstaff, AZ); n ¼ 36 (2.5%) Fortron (Johnson &
Johnson e Cordis Corporation, Bridgewater, NJ); n ¼ 53
(3.7%) Anaconda (Terumo Vascutek, Inchinnan Renfrew-
shire, Scotland UK), and n ¼ 5 (0.3%) others.
Baseline, intraoperative and follow-up clinical and imag-
ing data of patients were collected in a prospective vascular
database. After EVAR patients were followed with CT-
Angiography at 1 month, 12 months and then yearly.AAA size
All measurements were performed directly and not ob-
tained from radiology reports. A vascular dedicated digital
workstation (TeraRecon Aquarius Workstation, Terarecon,
Foster City, CA) was used for CT-scan imaging analysis and
three-dimensional (3D) reconstructions. The preoperative
CT scan was considered the baseline study. The AAA size
was deﬁned as the maximum sac diameter and measured at
baseline and at each follow-up year by experienced oper-
ators from standard axial two-dimensional CT scans using
digital calipers from cut ﬁlms or perpendicularly to the
centerline of ﬂow on CT reconstructions. On the two
dimensional CT scan, sac diameter measurements were
based on the shortest outside transverse diameter on the
largest cut of the aneurysms. The minor axis was used to
avoid overestimation of AAA as a result of tortuosity of the
aorta. Diameter changes 5 mm between two following CT
studies were considered signiﬁcant for sac regression(shrinkage) or expansion based on the Standardized
Reporting Practices in Vascular Surgery.1Patient subgroups and deﬁnition
Patients were categorized into two groups: the persisting
shrinkage group included patients with 5 mm AAA
diameter spontaneous shrinkage continuing until the end of
follow-up without any reintervention or conversion. The
remaining patients were assigned to the nonpersisting
shrinkage group. Newer stentgrafts were deﬁned as those
introduced in use after 2004 or currently in use without
modiﬁcations.Outcome measures
Primary outcome was the rate of persisting shrinkage of
AAA diameter. Secondary outcomes included late all cause
survival and freedom from late aneurysm-related death and
rupture rates.Statistical analysis
Data were presented as numbers with percentages for
categorical variables and mean  standard deviation or
median and interquartile ranges (IQR) as required, for
continuous variables. AAA shrinkage was assessed as a
dichotomized variable using the 5 mm value as cutoff for
relevant shrinkage.
To measure the efﬁcacy of the repair related to persisting
shrinkage, all cause survival, freedom from AAA-related
death and freedom from AAA rupture rates between pa-
tients with and without persisting shrinkage were compared
using Kaplan Meier analysis with log rank test.
Because the follow-up dates were not the same for each
device, the rates of AAA persisting shrinkage between new
generation and old generation devices and between
different stentgraft models were also compared using
KaplaneMeier analysis.
Clinical and anatomical predictive factors for persisting
shrinkage were analyzed using Cox models with backward
stepwise selection of potential confounding factors. The
relationship of each device model with persisting shrinkage
was tested in unadjusted and adjusted analyses using Cox
models.
A value of p < .05 was considered signiﬁcant for all
analyses.
Statistical analysis was performed with SPSS (Version 20,
SPSS, Chicago, IL).
RESULTS
Of 1,450 patients, the mean age was 73.1  7.7 years and
1325 were male. Mean preoperative aneurysm diameter
was 55.2  10.3 mm. During a median follow-up of 45
months (IQR 21e79, mean 53.3  42.3), any aneurysm
shrinkage (5 mm) was detected in 986 (68%) aneurysms.
The mean time for shrinkage occurrence was 19.02  20.1
months (median 13 months). During follow-up, 197 late
reinterventions (mainly endovascular procedures including
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crossover bypass, thrombectomy, iliac stent, etc.) and 58
late conversions (as a result of aneurysm sac expansion
associated with endoleak or migration unmanageable with,
or after failure of, endovascular procedure and one sten-
tgraft infection) were performed. Forty late branch occlu-
sions occurred, more likely in the any-shrinkage aneurysms
group (34/986 vs. 6/464) and 25 required reintervention.
When only AAAs with persisting shrinkage (ie, 5 mm
AAA diameter shrinkage spontaneously occurring and
continuing until the end of follow-up without any reinter-
vention or conversion) were accounted, the rate was 53%
(768). Persisting shrinkage developed after a mean time of
17.82  19.6 months (median 13 months) after repair.
Demographic, clinical and main morphology baseline char-
acteristics of the persisting shrinkage vs. nonpersisting
shrinkage groups of patients are shown in Table 1. Mean
preoperative aneurysm diameter was comparable between
the two groups (54.8 mm vs. 55.62 mm), but neck length
was about 1.5 mm longer in the persisting shrinkage group:
25.9 mm vs. 24.5 mm; p ¼ .021. Persisting shrinkage was
signiﬁcantly more frequent in smokers (60.8% vs. 53.7%;
p ¼ .007) and hyperlipidemic patients (37.2% vs. 31.8%;
p ¼ .031) and less likely in patients with renal failure (12.6%
vs. 16.7%; p ¼ .030) and in those under anticoagulants
(6.1% vs. 8.8%) even though borderline statistical relevance
was achieved for the last (p ¼ .056). Distribution of
different stentgraft devices in the persisting shrinkage and
nonpersisting shrinkage groups of patients are shown in
Table 2. Overall, 906 (62.5%) stentgrafts were of new
generation and these were signiﬁcantly more common in
the persisting shrinkage group: 69.1% vs. 54.9%; p ¼ .0001.
When the association of persisting shrinkage with po-
tential predictors and between different stentgraft models
was tested with Cox multivariate analysis, the only clinicalTable 1. Baseline characteristics and demographics of patients with an
Shrinkage
(n ¼ 768)
N %
Age (mean  SD) 72.11  7.5
Males 709 92
Hypertension 587 76
CAD 343 44
Hyperlipidemia 286 37
PAD 92 12
Diabetes 97 12
COPD 376 49
Chronic renal failure 97 12
Smoking 467 60
Cerebrovascular disease 103 13
Anticoagulants 47 6
Antiplatelets 390 50
Aneurysm diameter (mean  SD) 54.82  10.2
Neck length (mean  SD) 25.92  11.2
Neck diameter (mean  SD) 23.49  3.3
Neck thrombus 51 6
Aortic thrombus 374 48
CAD ¼ coronary artery disease; PAD ¼ peripheral artery disease; COPand morphological factors retained in the ﬁnal model were
large aneurysm diameter, younger age and lack of aortic
thrombus (Table 3). Furthermore, persisting shrinkage was
signiﬁcantly and positively associated with new generation
devices (OR 1.99, 95% CI 1.69e2.33; p ¼ .0001), Zenith (OR
1.33, 95% CI 1.18e1.51; p ¼ .0001) and Endurant (OR 1.52,
95% CI 1.11e2.09; p ¼ .010), and negatively associated
with AneuRx stentgraft (OR 0.57, 95% CI 0.48e0.69;
p ¼ .0001).
According to KaplaneMeier analysis, cumulative rates of
persisting shrinkage were 25.8% at 1 year, 63% at 3 years,
68.8% at 5 years, and 72.6% at 10 years (Fig. 1). Kaplane
Meier analysis conﬁrmed persisting shrinkage rates signiﬁ-
cantly higher for Zenith (log rank p < .0001) and Endurant
(log rank, p ¼ .013) devices and lower for the AneuRx (log
rank p < .0001) device, whereas no signiﬁcant effect on
persisting shrinkage was found for the other models (Talent,
Excluder, Anaconda, Fortron) (Fig. 2). Furthermore, persist-
ing shrinkage rates were signiﬁcantly higher for the overall
new generation device group: 31.3% vs. 17.3% at 1 year,
72.5% vs. 48.8% at 3 years, and 79.8% vs. 53.6% at 5 years
for new generation vs. old generation, respectively (log rank
test p < .0001) (Fig. 3). As the Excluder and Anaconda
devices changed from old to new generation during the
study period and both generations were included in the
study, the effect of generation changes on persisting sac
shrinkage for these two speciﬁc brands was also tested. The
Excluder new model was found to be associated with higher
persisting shrinkage rates compared with the older model
(log rank p < .0001), whereas no signiﬁcant changes in rates
of persisting shrinkage were noted between Anaconda de-
vices of new and old generation.
Survival rates from all causes in the long term were
higher for patients in the persisting shrinkage group: 95.9%
vs. 89.2% at 1 year, 84.1% vs. 77.8% at 3 years, 69.6% vs.d without 5 mm persisting aneurysm shrinkage.
No shrinkage
(n ¼ 682)
p
N %
74.21  7.8 <.0001
.3 616 90.3 .190
.4 528 77.4 .663
.7 328 48.1 .205
.2 217 31.8 .031
97 14.1 .212
.6 82 12 .749
331 48.5 .875
.6 114 16.7 .03
.8 366 53.7 .007
.4 96 14.1 .760
.1 60 8.8 .056
.8 328 48.1 .318
55.62  10.4 .141
24.53  10.4 .021
23.50  3.7 .992
.6 38 5.6 .443
.7 334 49 .958
D ¼ chronic obstructive pulmonary disease.
Table 2. Stentgraft distribution and >5 mm persisting aneurysm
shrinkage.
n Shrinkage
(n ¼ 768)
No shrinkage
(n ¼ 682)
p
N % N %
Zenith Cook 622 389 50.7 233 34.2 <.0001
Excluder Gore 236 121 15.6 115 16.9 .568
Endurant Medtronic 83 33 4.3 50 7.3 .017
Talent Medtronic 179 90 11.7 89 13 .472
AneuRx Medtronic 236 89 11.6 147 21.6 <.0001
Anaconda Vascutek 53 24 3.1 29 4.3 .265
Fortron Cordis 36 20 2.6 16 2.3 .866
Others 5 3 0.4 2 0.2 .627
New devices 906 531 69.1 375 55 <.0001
E. Cieri et al. 19565.2% at 5 years, and 53% vs. 38.1% at 10 years, for the
persisting shrinkage vs. nonpersisting shrinkage group
(Fig. 4).
Patients with persisting shrinkage showed signiﬁcantly
superior freedom from late AAA-related deaths: 100% vs.
99.5% at 1 year, 100% vs. 98.8% at 3 years, 99.7% vs. 98.5%
at 5 years, and 99.7% vs. 95.3% at 10 years for the persisting
shrinkage vs. nonpersisting shrinkage group (Fig. 5).
During follow-up, 17 aneurysm ruptures were recorded,
only one in the persisting shrinkage group in a patient
without detectable complications at the last assessment
performed 15 months before rupture (aneurysm rupture
was managed in outside hospital and no details were pro-
vided). Cumulative freedom form rupture rates were 100%
vs. 100% at 1 year, 100% vs. 99.5% at 3 years, 99.7% vs.
98.3% at 5 years, and 99.7% vs. 92.8% at 10 years for the
persisting shrinkage vs. nonpersisting shrinkage group.
Patients with persisting shrinkage showed few endoleak
occurrences in the overall follow-up period: freedom from
endoleak rates were 90.6% at 5 years and 84.2% at 10 years
(in nonshrinkage group corresponding rates 63.3% and
36.6%; log rank test p < .0001).
Nonshrinking aneurysms might be dependent on type II
endoleaks that are recognized as a non-device related
marker of persisting sac pressurization. We thereby re-
analyzed the relationship between device models and per-
sisting5 mm shrinkage after exclusion of all AAA with type
II endoleak (n ¼ 213). The relationships remained un-
changed conﬁrming a signiﬁcant effect of Zenith, Endurant,Table 3. Independent predictors of 5 mm persisting aneurysm
shrinkage. Cox regression analysis.
OR p 95% CI for OR
Lower Upper
Age 0.978 <.0001 0.969 0.987
Aneurysm diameter 1.010 .006 1.003 1.017
Aortic thrombus 0.863 .045 0.747 0.997
New devices 1.986 <.0001 1.693 2.329
Zenith Cook 1.334 <.0001 1.176 1.514
Endurant Medtronic 1.523 .01 1.108 2.092
AneuRx Medtronic 0.574 <.0001 0.477 0.688and AneuRx (negative) devices on persisting shrinkage rates
in the remaining 1,237 EVAR repairs.DISCUSSION
Relevant shrinkage of aneurysmal sac can spontaneously
occur and persist in the long term, representing a robust
indicator of durable treatment success after most current
EVAR repairs. In the presence of persisting aneurysm
diameter regression of 5 mm or more, the risk of aneurysm-
related death and aneurysm rupture is inconsistent with
0.3% rate at 10 years according to our data.
Aneurysmal sac change after EVAR is a time-dependent
event and can be assumed as a marker of EVAR durability
that is challenging to address.6,7 Relevant (5mm) aneurysm
sac regression takes time to develop after sac depressuriza-
tion related to stentgraft deployment, but can also reverse
over time especially when an abrupt onset of speciﬁc EVAR-
related complications (eg, migration, neck enlargement with
related endoleak), compromising an initial technically suc-
cessful repair, occurs. Because of the dynamic behavior of the
aneurysmal shrinkage process, only aneurysms with sac
regression spontaneously occurring and maintaining in the
long term (and not inﬂuenced by any additional procedure
aimed to revise complications potentially leading to aneu-
rysm pressurization) should be considered a reliable surro-
gate marker of durable successful EVAR repair. Such a
persisting shrinkage marker was used in our study. Persisting
sac shrinkage does not occur soon after aneurysm repair (in
our study it developed after a mean of 17.82 19.6 months;
median 13months), therefore shrinkage sac rates assessed in
the early years (1e2 years) after EVAR might be under-
estimated. Conversely, shrinkage rates assessed at the mid-
term (2e5 years) after EVAR might likely be overestimated
as aneurysms losing shrinkage for re-pressurization of the sac
at a later time can be missed.
Despite the restrictive criteria, our incidence of persisting
shrinkage was not irrelevant and persisted in more than
two-thirds of patients at 10 years (68.8% at 5 years and
72.6% at 10 years). In the study of Houbballah et al.,7 sac
shrinkage occurred in only 28.8% of 371 EVAR patients after
an average of 26 months’ follow-up. These rates, about half
of ours, were likely affected by the diverse criteria to deﬁne
shrinkage and the inclusion of most ﬁrst generation devices
(not used in our study) more prone to developing EVAR-
speciﬁc complications not allowing aneurysm seal and sac
shrinkage. There is indeed growing evidence, conﬁrmed by
our data, to support that recent stentgraft devices perform
better than older models in the long term.8e10 High per-
sisting shrinkage rates over time can be similarly achieved
with most last generation models of devices currently in use
(eg, Zenith Cook, Endurant Medtronic, Excluder Goretex),
even though this message should be interpreted cautiously
as some of the newest stentgrafts have not matured
enough since their introduction to assess the persistence of
long-term beneﬁt (10 years or more).
Differences in graft materials, modularity, and conﬁgu-
ration have been reported among major factors inﬂuencing
Figure 1. Proportion of patients with 5 mm persisting aneurysm shrinkage over time.
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speciﬁc effects on the aortic wall after implantation.5,6,11e
14 Nevertheless, the ﬁndings are in part weakened by the
inclusion of early stentgraft devices that have been
currently improved.5,11e13 Furthermore, comparisons of
speciﬁc aortic stentgraft devices on changes in aortic
morphology are challenging because of plain differences in
implants related to aortic anatomy, patient settings, oper-
ator technical preferences and speciﬁc instruction for use
(IFU). In the study of Broker et al.,13 the worse performance
of 29 Excluder compared with 46 AneuRx and 47 Zenith
(shrinkage rates at 18 months: 5.5%, 18.9% and 11%,
respectively; p < .05) was affected by the inclusion of the
low-porosity devices not currently in use with the new
Excluder generation stentgraft. Similarly, Bertges et al.5
found aneurysm size regression rates at 2 years lower
with two older models (Excluder and AneuRx) compared
with Talent device. In our series, the Excluder and the
Anaconda devices included both old and new generation
models and showed no signiﬁcant effect on the develop-
ment of shrinkage. Nevertheless, when separately analyzed,
the new Excluder devices showed signiﬁcantly higher per-
sisting shrinkage rates compared with the older devices (log
rank p < .0001).
Similar to our data, Houballah et al.7 recently found that
signiﬁcant sac shrinkage (>5 mm) after EVAR was associ-
ated with signiﬁcantly longer survival (96 vs. 93 months)
and no rupture or surgical conversion. Nevertheless, in our
study the main difference in survival rates between per-
sisting and nonpersisting shrinking AAA was detected fromthe ﬁrst year after repair, whereas persisting shrinkage
occurred later. Other factors may have been responsible for
early survival beneﬁt and late sac persisting shrinkage, but
these require further analysis. We observed that persisting
shrinkage was more likely in aneurysms without aortic
thrombus, with large diameter, and in younger patients. A
superior health care/drug therapy in the last group of pa-
tients with higher cardiovascular risk proﬁle might have had
a role in promoting better early survival and late sac
shrinkage. Furthermore, it may be hypothesized that denser
and less ﬂuid clot deposition as well as more calciﬁed vessel
atherosclerosis involving aortic wall in older patients,
allowed less sac depressurization. Several studies also
supported old age7,15,16 and presence and volume of mural
aortic thrombus5,7,17,18 correlated with decreased aneurysm
shrinkage. Cornelissen et al.19 recently showed, using a
magnetic resonance study of aneurysm morphology, that
the presence of unorganized thrombus years after EVAR
was signiﬁcantly associated with nonshrinking aneurysms.
In our study, AAA baseline size was positively correlated
with rate of aneurysm persisting shrinkage. In 2004,
Greenberg et al.6 also found that larger aneurysm sacs
tended to have a greater area of sac reduction in a core lab
re-analysis of electronically digited CT images of 1,506 EVAR
patients. Potential explanation may rely on a higher pro-
portion of decrease in wall tension after sac depressuriza-
tion in larger diameter vs. smaller diameter aneurysms by
LaPlace law (s ¼ 2rP).
Device-induced aneurysm sac signiﬁcant changes might
alter the device integrity.20,21 Improved device designs
Figure 2. Proportion of patients with 5 mm persisting aneurysm shrinkage over time according to stentgraft model.
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Figure 3. Proportion of patients with 5 mm persisting aneurysm shrinkage over time in new generation vs. old generation models.
Figure 4. All cause survival according to presence of 5 mm persisting aneurysm shrinkage.
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Figure 5. Freedom from aneurysm-related death according to presence of 5 mm persisting aneurysm shrinkage.
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be more likely to be crushed by the aneurysmal sac collapse
together with loss of patency. In our study, iliac branch
occlusions were more likely found in aneurysms with any
shrinkage; 14 asymptomatic occlusions occurred in the
persisting shrinkage group. Even though the overall inci-
dence of branch occlusion was limited (3.7% over 10 years),
the complication did not disappear with new device models
(data not shown). Further improvements in device tech-
nology could help manage device material fatigue in new
devices.
Limitations of the study include the retrospective design
with related disadvantages in accuracy for data recording
and ensuring patient compliance. Furthermore, there were
no volumetric analysis or detailed assessment of
morphology predictors of aneurysm regression, as distri-
bution and severity of calciﬁcations, volume and consis-
tency of aortic thrombus, number and size of lumbar
arteries, etc. Device selection was intentional and we did
not analyze to what extent IFU were followed and inﬂu-
enced sac outcome with each device. Finally, the effect of
improved durability with new generation devices on costs
was outside the topic of the study.
Conclusions
In this study, signiﬁcant shrinkage (5 mm) of aneurysm sac
spontaneously occurred in more than 72% EVARs and per-
sisted at 10 years. Even though the behavior of aneurysmal
sac depends on various and largely undeﬁned factors,
including the type of stentgraft, equivalent high persisting
sac shrinkage rates can be achieved using most devices of
current generation. Differential rate of spontaneouspersisting shrinkage rates must be considered when deter-
mining the durability and assessing success or failure of
EVAR.
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